---
title: "Rinvoq (upadacitinib) in rheumatoid arthritis: Specific populations questions"
description: "Specific populations questions on Rinvoq (upadacitinib) in rheumatoid arthritis, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Questions: Does RINVOQ need a dose adjustment for kidney or liver impairment? Can patients breastfeed while taking RINVOQ? Can RINVOQ be used during pregnancy? 3 questions quoted from 1 source."
canonical: "https://www.evicenter.com/medical-information/rinvoq--rheumatoid-arthritis/specific-populations"
published: "2026-11-12T22:05:36-05:00"
modified: "2026-11-14T01:54:55-05:00"
---

# Rinvoq (upadacitinib) in rheumatoid arthritis: Specific populations questions

Manufacturer: AbbVie Inc.  
Prescribing information: [Rinvoq](https://www.rinvoqhcp.com/prescribinginfo)

## Specific populations

<a id="rinvoq-organ-impairment"></a>

### Does RINVOQ need a dose adjustment for kidney or liver impairment?

> “In RA, PsA, AS, nr-axSpA, and GCA:
>
> No dose adjustment is required for mild, moderate, or severe renal impairment.<sup>1</sup>
>
> No dose adjustment is required for mild or moderate hepatic impairment.<sup>1</sup>
>
> RINVOQ is not recommended in patients with<sup>1</sup>:
>
> Active hepatitis B or hepatitis C
> Severe hepatic impairment (Child-Pugh C)
>
> RINVOQ has not been studied in end-stage renal disease (eGFR <15 mL/min/1.73 m<sup>2</sup>).<sup>1</sup>”

Source: [RINVOQ: RINVOQ® (upadacitinib) Dosing for RA, PsA, AS, nr-axSpA, and GCA, captured 2026-11-08](https://www.rinvoqhcp.com/rheumatology/dosing-lab-monitoring#:~:text=In%20RA%2C%20PsA%2C%20AS%2C%20nr%2DaxSpA%2C,renal%20disease%20%28eGFR%20%3C15%20mL%2Fmin%2F1.73)

<a id="rinvoq-breastfeeding"></a>

### Can patients breastfeed while taking RINVOQ?

> “There are no data on the presence of RINVOQ in human milk, the effects on the breastfed infant, or the effects on milk production. Available data in animals have shown the excretion of RINVOQ in milk. Advise patients that breastfeeding is not recommended during treatment with RINVOQ and for 6 days after the last dose.”

Source: [RINVOQ: RINVOQ® (upadacitinib) Dosing for RA, PsA, AS, nr-axSpA, and GCA, captured 2026-11-08](https://www.rinvoqhcp.com/rheumatology/dosing-lab-monitoring#:~:text=There%20are%20no%20data%20on,days%20after%20the%20last%20dose.)

<a id="rinvoq-pregnancy"></a>

### Can RINVOQ be used during pregnancy?

> “Based on findings in animal studies, RINVOQ may cause fetal harm when administered to a pregnant woman. Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment with RINVOQ and for 4 weeks after the final dose. Verify pregnancy status of females of reproductive potential prior to starting treatment with RINVOQ.”

Source: [RINVOQ: RINVOQ® (upadacitinib) Dosing for RA, PsA, AS, nr-axSpA, and GCA, captured 2026-11-08](https://www.rinvoqhcp.com/rheumatology/dosing-lab-monitoring#:~:text=Based%20on%20findings%20in%20animal,to%20starting%20treatment%20with%20RINVOQ.)

## Related pages
- [Medical information: Rinvoq (upadacitinib): Rheumatoid arthritis](https://www.evicenter.com/medical-information/rinvoq--rheumatoid-arthritis)
- [Indication](https://www.evicenter.com/medical-information/rinvoq--rheumatoid-arthritis/indication)
- [Pharmacology](https://www.evicenter.com/medical-information/rinvoq--rheumatoid-arthritis/pharmacology)
- [Clinical trials](https://www.evicenter.com/medical-information/rinvoq--rheumatoid-arthritis/clinical-trials)
- [Safety](https://www.evicenter.com/medical-information/rinvoq--rheumatoid-arthritis/safety)
- [Drug interactions](https://www.evicenter.com/medical-information/rinvoq--rheumatoid-arthritis/drug-interactions)
- [Dosing and administration](https://www.evicenter.com/medical-information/rinvoq--rheumatoid-arthritis/dosing-and-administration)
- [Storage and supply](https://www.evicenter.com/medical-information/rinvoq--rheumatoid-arthritis/storage-and-supply)
- [Access and coverage](https://www.evicenter.com/medical-information/rinvoq--rheumatoid-arthritis/access-and-coverage)
